A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Inclusion Criteria:
Exclusion Criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Harlingen, Texas 78550, United States
Irving, Texas 75039, United States
Ciudad de Buenos Aires, C1431, Argentina
Ciudad de San Miguel de Tucuman, T4000AXL, Argentina
South Woodville, 5011, Australia
Belo Horizonte, 30130 100, Brazil
São José do Rio Preto, 15090-000, Brazil
São Paulo, 04266 010, Brazil
St. John's, Newfoundland and Labrador A1C 5B8, Canada
Dresden, 01307, Germany
Freiburg im Breisgau, 79106, Germany
Surat, 395002, India
Kitakyushu-shi, 807-8556, Japan
Osaka, 550 0006, Japan
Shimotsuga Gun, 321 0293, Japan
San Luis Potosí City, 78213, Mexico
Krakow, 30-002, Poland
Staffordshire, ST6 7AG, United Kingdom